טוען...
Dimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells
OBJECTIVE: To elucidate the immunomodulatory effects of dimethyl fumarate (DMF) on B cells in patients with relapsing MS receiving DMF as a “1st-line” vs “2nd-line” therapy. METHODS: B cells were isolated from 43 patients with MS at baseline and after 15-week DMF therapy. Phenotype and functional ma...
שמור ב:
| הוצא לאור ב: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Lippincott Williams & Wilkins
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6192691/ https://ncbi.nlm.nih.gov/pubmed/30345334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000508 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|